AR054550A1 - Metodos para tratar la epileptogenesis - Google Patents
Metodos para tratar la epileptogenesisInfo
- Publication number
- AR054550A1 AR054550A1 ARP060102976A ARP060102976A AR054550A1 AR 054550 A1 AR054550 A1 AR 054550A1 AR P060102976 A ARP060102976 A AR P060102976A AR P060102976 A ARP060102976 A AR P060102976A AR 054550 A1 AR054550 A1 AR 054550A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- phenyl
- alkyl
- methods
- subject
- Prior art date
Links
- 230000008579 epileptogenesis Effects 0.000 title abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69862505P | 2005-07-12 | 2005-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054550A1 true AR054550A1 (es) | 2007-06-27 |
Family
ID=37637731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102976A AR054550A1 (es) | 2005-07-12 | 2006-07-11 | Metodos para tratar la epileptogenesis |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070021501A1 (https=) |
| EP (1) | EP1906946A2 (https=) |
| JP (1) | JP2009501223A (https=) |
| KR (1) | KR20080028485A (https=) |
| CN (1) | CN101309680A (https=) |
| AR (1) | AR054550A1 (https=) |
| AU (1) | AU2006269462A1 (https=) |
| BR (1) | BRPI0613010A2 (https=) |
| CA (1) | CA2615127A1 (https=) |
| EA (1) | EA200800295A1 (https=) |
| EC (1) | ECSP088172A (https=) |
| IL (1) | IL188728A0 (https=) |
| NO (1) | NO20080739L (https=) |
| TW (1) | TW200744575A (https=) |
| WO (1) | WO2007008551A2 (https=) |
| ZA (1) | ZA200801402B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2307035T3 (da) * | 2008-05-16 | 2014-01-20 | Nono Inc | Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| CN109939092B (zh) * | 2013-03-12 | 2022-03-22 | 比皮艾思药物研发有限公司 | 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物 |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| HUE066912T2 (hu) * | 2015-08-24 | 2024-09-28 | Zogenix International Ltd | Lennox-Gastaut szindróma kezelési eljárása fenfluramin alkalmazásával |
| WO2017150903A1 (en) | 2016-02-29 | 2017-09-08 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds, processes for preparing them and their uses |
| US20190022166A1 (en) * | 2017-07-18 | 2019-01-24 | Creative Bio-Peptides Inc. | Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders |
| USRE50630E1 (en) | 2017-10-31 | 2025-10-14 | Creative BioPeptides, Inc. | Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain |
| CN109920550A (zh) * | 2018-12-25 | 2019-06-21 | 天津大学 | 一种基于dMRI研究青少年肌阵挛性癫痫的方法 |
| US11510961B2 (en) | 2019-12-19 | 2022-11-29 | Creative Bio-Peptides, Inc. | Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof |
| CN115501344A (zh) * | 2022-09-29 | 2022-12-23 | 重庆医科大学 | 一种铁螯合剂的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) * | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3265728A (en) * | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| AU3304997A (en) * | 1996-05-31 | 1998-01-05 | Southern Illinois University | Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation |
| DK1156798T3 (da) * | 1999-02-09 | 2003-11-03 | Univ Virginia | Felbamat-afledte forbindelser |
| US7122576B2 (en) * | 2001-02-27 | 2006-10-17 | Plata-Salaman Carlos R | Carbamate compounds for use in preventing or treating bipolar disorder |
| ES2262801T3 (es) * | 2001-02-27 | 2006-12-01 | Ortho-Mcneil Pharmaceutical, Inc. | Uso de un compuesto de carbamato para la prevencion o el tratamiento de trastorno bipolar. |
-
2006
- 2006-07-06 US US11/481,626 patent/US20070021501A1/en not_active Abandoned
- 2006-07-07 AU AU2006269462A patent/AU2006269462A1/en not_active Abandoned
- 2006-07-07 EP EP06786434A patent/EP1906946A2/en not_active Withdrawn
- 2006-07-07 KR KR1020087003269A patent/KR20080028485A/ko not_active Withdrawn
- 2006-07-07 WO PCT/US2006/026277 patent/WO2007008551A2/en not_active Ceased
- 2006-07-07 CN CNA2006800333910A patent/CN101309680A/zh active Pending
- 2006-07-07 JP JP2008521432A patent/JP2009501223A/ja not_active Withdrawn
- 2006-07-07 BR BRPI0613010-0A patent/BRPI0613010A2/pt not_active IP Right Cessation
- 2006-07-07 EA EA200800295A patent/EA200800295A1/ru unknown
- 2006-07-07 CA CA002615127A patent/CA2615127A1/en not_active Abandoned
- 2006-07-11 TW TW095125162A patent/TW200744575A/zh unknown
- 2006-07-11 AR ARP060102976A patent/AR054550A1/es not_active Application Discontinuation
-
2008
- 2008-01-10 IL IL188728A patent/IL188728A0/en unknown
- 2008-02-11 ZA ZA200801402A patent/ZA200801402B/xx unknown
- 2008-02-11 NO NO20080739A patent/NO20080739L/no not_active Application Discontinuation
- 2008-02-12 EC EC2008008172A patent/ECSP088172A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101309680A (zh) | 2008-11-19 |
| NO20080739L (no) | 2008-04-10 |
| KR20080028485A (ko) | 2008-03-31 |
| WO2007008551A3 (en) | 2008-06-19 |
| AU2006269462A1 (en) | 2007-01-18 |
| EA200800295A1 (ru) | 2008-12-30 |
| ECSP088172A (es) | 2008-03-26 |
| ZA200801402B (en) | 2009-10-28 |
| EP1906946A2 (en) | 2008-04-09 |
| CA2615127A1 (en) | 2007-01-18 |
| TW200744575A (en) | 2007-12-16 |
| JP2009501223A (ja) | 2009-01-15 |
| IL188728A0 (en) | 2008-11-03 |
| BRPI0613010A2 (pt) | 2010-12-14 |
| US20070021501A1 (en) | 2007-01-25 |
| WO2007008551A2 (en) | 2007-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088172A (es) | Metodos para tratar la epileptogenesis | |
| ECSP088179A (es) | Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos | |
| CO6382111A2 (es) | Uso de 2-fenil-1,2-etanodiol-(id) carbamatos para tratar epileptogenesis y epilepsia | |
| CO6180427A2 (es) | Tratamiento de los trastornos generalizados del desarrollo | |
| AR033426A1 (es) | Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento | |
| AR035756A1 (es) | Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos | |
| GEAP202215588A (en) | N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors | |
| AR064241A1 (es) | Metodos para el tratamiento de la depresion | |
| ECSP077395A (es) | Compuesto de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos | |
| AR054524A1 (es) | Metodos y formas de dosificacion para reducir los efectos secundarios de compuestos de carbamato | |
| AR029005A1 (es) | FORMULACION LíQUIDA ESTABLE SIN AGUA O CASI SIN AGUA DE BENCIMIDAZOLES SUSTITUIDOS, PROCESO PARA SU PREPARACIoN, USO DE ESTA FORMULACIoN, Y USO DE POLIETILENGLICOL Y UNA SAL DE SODIO O POTASIO DE UN INHIBIDOR DE H+, K+-ATP ASA | |
| AR052885A1 (es) | Metodos para el control del intervalo qt | |
| CO6180505A2 (es) | Metodos para el tratamiento de transtornos cocleares y vestibulares | |
| DK1408953T3 (da) | Carbamatforbindelser til anvendelse til forebyggelse eller behandling af bipolær sygdom | |
| AR032876A1 (es) | Compuestos de carbamato para utilizar en la prevencion o tratamiento de los trastornos psicoticos | |
| EA200800422A1 (ru) | Способы лечения заболеваний, обусловленных химическими веществами | |
| CO6160292A2 (es) | Metodos de tratamiento de transtornos de comportamiento perturbador 877 | |
| PE20040906A1 (es) | Derivados morfolinicos como agonistas de dopamina | |
| AR077884A1 (es) | (4-(5-aminometil- fenil)-piperidin-1-il)-1h-indol-3-il)-metanonas disustituidas | |
| AR051314A1 (es) | Metodos de tratamiento de la epileptogenesis y la epilipsia. composicion farmaceutica y kit. | |
| AR032907A1 (es) | Uso de compuestos carbamatos para la prevencion o tratamiento de trastornos de ansiedad | |
| CR9766A (es) | Metodos para el tratamiento de trastornos relacionados con sustancias | |
| AR033428A1 (es) | Compuestos carbamatos para su uso en la prevencion o tratamiento de trastornos bipolares | |
| AR034785A1 (es) | Compuestos de carbamato para utilizarse en la prevencion o tratamiento de dolor neuropatico y dolor asociado con cefalea migranosa y cefalea acuminada | |
| AR035757A1 (es) | Uso de carbamatos para la fabricacion de medicamentos para prevenir o tratar un trastorno bipolar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |